Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The event is scheduled for August 13, 2024, with Clene's presentation set for 11:30 am EST.
Clene specializes in improving mitochondrial health and protecting neuronal function to treat conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's management will deliver a presentation and host one-on-one investor meetings during the conference.
Interested parties can access a webcast of the presentation through Clene's website in the 'Events' section or via a provided registration link.
Clene Inc. (Nasdaq: CLNN), un'azienda biopharmaceutical clinica focalizzata sulle malattie neurodegenerative, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale di Crescita & Vetrina di Aziende Private di Canaccord Genuity. L'evento è programmato per 13 agosto 2024, con la presentazione di Clene prevista per le 11:30 am EST.
Clene si specializza nel migliorare la salute mitocondriale e proteggere la funzione neuronale per trattare condizioni come sclerosi laterale amiotrofica (SLA) e sclerosi multipla (SM). La direzione dell'azienda presenterà e organizzerà incontri individuali con gli investitori durante la conferenza.
Le parti interessate possono accedere a un webcast della presentazione attraverso il sito web di Clene nella sezione 'Eventi' o tramite un link di registrazione fornito.
Clene Inc. (Nasdaq: CLNN), una empresa biofarmacéutica en etapa clínica centrada en enfermedades neurodegenerativas, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento y Vitrina de Empresas Privadas de Canaccord Genuity. El evento está programado para el 13 de agosto de 2024, con la presentación de Clene programada para las 11:30 am EST.
Clene se especializa en mejorar la salud mitocondrial y proteger la función neuronal para tratar condiciones como esclerosis lateral amiotrófica (ELA) y esclerosis múltiple (EM). La dirección de la empresa presentará y organizará reuniones individuales con inversores durante la conferencia.
Las partes interesadas pueden acceder a una transmisión web de la presentación a través del sitio web de Clene en la sección 'Eventos' o mediante un enlace de registro proporcionado.
Clene Inc. (Nasdaq: CLNN), 신경퇴행성 질환에 중점을 둔 임상 단계의 바이오제약 회사가 Canaccord Genuity 제44회 연례 성장 회의 및 사적 기업 전시회에 참여한다고 발표했습니다. 이 행사는 2024년 8월 13일로 예정되어 있으며 Clene의 발표는 11:30 am EST로 예정되어 있습니다.
Clene은 미토콘드리아 건강을 개선하고 신경 기능을 보호하여 근위축성 측삭 경화증 (ALS) 및 다발성 경화증 (MS)과 같은 질환을 치료하는 데 전문화되어 있습니다. 회사 경영진은 회의 중에 발표를 하고 투자자와의 일대일 미팅을 주최할 것입니다.
관심 있는 분들은 Clene의 웹사이트 '이벤트' 섹션 또는 제공된 등록 링크를 통해 발표의 웹캐스트를 시청할 수 있습니다.
Clene Inc. (Nasdaq: CLNN), une entreprise biopharmaceutique en phase clinique axée sur les maladies neurodégénératives, a annoncé sa participation à la 44e Conférence Annuelle de Croissance et Vitrine des Entreprises Privées de Canaccord Genuity. L'événement est prévu pour le 13 août 2024, avec la présentation de Clene programmée pour 11 h 30 EST.
Clene se spécialise dans l'amélioration de la santé mitochondriale et la protection de la fonction neuronale pour traiter des conditions telles que sclérose latérale amyotrophique (SLA) et sclérose en plaques (SEP). La direction de l'entreprise fera une présentation et organisera des réunions individuelles avec les investisseurs pendant la conférence.
Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via le site web de Clene dans la section 'Événements' ou via un lien d'inscription fourni.
Clene Inc. (Nasdaq: CLNN), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf neurodegenerativen Erkrankungen, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz & Private Company Showcase von Canaccord Genuity angekündigt. Die Veranstaltung ist für den 13. August 2024 angesetzt, wobei Clenes Präsentation um 11:30 Uhr EST geplant ist.
Clene spezialisiert sich auf die Verbesserung der mitochondrialen Gesundheit und den Schutz der neuronalen Funktion, um Erkrankungen wie amyotrophe Lateralsklerose (ALS) und multiple Sklerose (MS) zu behandeln. Das Management des Unternehmens wird während der Konferenz eine Präsentation halten und Einzelgespräche mit Investoren führen.
Interessierte können über die Website von Clene im Abschnitt ‚Veranstaltungen‘ oder über einen bereitgestellten Registrierungslink auf einen Webcast der Präsentation zugreifen.
- None.
- None.
SALT LAKE CITY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase and host 1x1 investor meetings.
Date: August 13, 2024
Time of Presentation: 11:30 am EST
Format: Presentation
1x1 Meetings: Please contact your Canaccord representative.
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
When is Clene Inc. (CLNN) presenting at the Canaccord Genuity Conference?
What diseases does Clene Inc. (CLNN) focus on treating?
How can investors access Clene's (CLNN) presentation at the Canaccord Genuity Conference?
Will Clene Inc. (CLNN) be hosting one-on-one meetings at the Canaccord Genuity Conference?
